Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks

Psychopharmacology

Volumn 129, Issue 4, 1997, Pages 357-364

  Van Megen, Harold J G M ^a   Westenberg, Herman G M ^a   Den Boer, Johan A ^a   Slaap, Bernard ^a   Scheepmakers, Antoinette ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cholecystokinin; Human studies; Panic disorder; Serotonin

Indexed keywords

FLUVOXAMINE; OXAZEPAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TETRAGASTRIN;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HAMILTON SCALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOMETRY; SEROTONINERGIC SYSTEM; SINGLE BLIND PROCEDURE;

ADULT; FEMALE; FLUVOXAMINE; HUMANS; MALE; MODELS, PSYCHOLOGICAL; NEUROPSYCHOLOGICAL TESTS; PANIC DISORDER; TETRAGASTRIN;

EID: 0031043804     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050201     Document Type: Article

References (43)

1. Abelson PL, Nesse RM, Vinik A (1991) Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 29:1220-1223
2. Abelson JL, Nesse RM, Vinik A (1994) Pentagastrin infusion in patients with panic disorder II. Neuroendocrinology. Biol Psychiatry 36:84-96
3. Albus M, Zahn TP, Breier A (1992) Anxiogenic effects of yohimbine. I Behavioral, physiological and biochemical measures. Eur Arch Psychiatry 241:377-344
4. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-IIIR). APA, Washington D.C., USA
5. Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A (1994) The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur J Pharmacol 271:403-411
6. Black DW, Wesner R, Bowers W, Gabel J (1993) A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44-50
7. Bradwejn J, Koszycki MA (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151(2):261-263
8. Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85
9. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48:603-610
10. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992) Study on the replication of action of cholecystokinin in panic disorders. Am J Psychiatry 149:962-964
11. Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen HJGM, Westenberg HGM, Den Boer JA, Annable L (1994) The panicogenic effects of CCK-tetrapeptide are antagonized by L-365,260, a central CCK receptor antagonist in patients with panic disorder. Arch Gen Psychiatry 51:486-493
12. Charney DS, Heninger GR, Redmond DE (1983) Yohimbine induced and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 33:19-29
13. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR (1992) Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 86:273-282
14. Den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA, Kahn RS (1987) Effects of serotonin uptake inhibitors in anxiety disorders, a double blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2:21-32
15. Den Boer JA, Westenberg HGM, Klompmakers AA, van Lint LEM (1989) Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. Biol Psychiatry 26:612-622
16. Den Boer JA, Westenberg HGM (1990a) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102:85-94
17. Den Boer JA, Westenberg HGM (1990b) Behavioral, neuroendocrine and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 31:267-279
18. Derogatis LR, Lipman RS, Covi L (1973) SCL-90 An out patient psychiatryric rating scale: preliminary report. Psychopharmacol Bull 9:13-28
19. Dooley DJ, Klamt I (1993) Differential profile of the CCK-B receptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology 112:452-454
20. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychology 32:50-55
21. Hamilton M (1967) Development of the rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296
22. Hamilton A (1969) Diagnosis and rating of anxiety. Br J Psychiatry [Special Publication] 3:76-79
23. Hoehn Saric R, McLeod DR, Hipsley A (1993) Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 5: 321-326
24. Hout van den, Criez E (1984) Panic symptoms after inhalation of carbon-dioxide. Br J Psychiatry 144:503-507
25. Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139-1166
26. Kahn RS, Asnis GM, Wetzler S, Van Praag HM (1988a) Neuroendocrine evidence for the serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96:360-364
27. Kahn RS, Wetzler S, Van Praag HM, Asnis GM (1988b) Behavioural indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 25:101-104
28. Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA (1993) Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 33:542-546
29. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CCP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 30:973-984
30. Liebowitz MR, Fyer AJ, Gorman JM (1984) Lactate provocation of panic attacks. I. clinical and behavioral findings. Arch Gen Psychiatry 41:764-770
31. Liebowitz MR, Gorman JM, Fyer AJ (1985) Lactate provocation of panic attacks II. Biochemical and physiological findings. Arch Gen Psychiatry 42:709-719
32. Lines C, Challenor J, Traub M (1995) Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Pharmacol 39:235-242
33. Marks IM, Matthews AM (1979) Brief standard self-rating for phobic patients. Behav Res Ther 17:263-267
34. Montigny de C (1989) Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers. Arch Gen Psychiatry 46:511-517
35. 3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 103:1790-1794
36. 3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats. Naunyn-Schmiedeberg's Arch Pharmacol 347:111-114
37. Rex A, Fink H, Marsden CA (1994) Effects of BOC-CCK-4 and L-365,260 on cortical 5-HT release in guinea pigs on exposure to the elevated plus maze. Neuropharmacology 33:559-565
38. Targum SD, Marshall LE (1989), Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28:295-306
39. Van Megen HJGM, Den Boer JA, Westenberg HGM (1994) Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449-455
40. Van Megen HJGM, Den Boer JA, Westenberg HGM (1996) Single blind dose response study with cholecystokinin (CCK-4) in panic disorder patients. Eur Neuropsychopharmacol 6:187-194
41. 3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology 110:213-218
42. Westenberg HGM, Den Boer JA (1994) The neuropharmacology of anxiety: a review on the role of serotonin. In: Den Boer JA, Sitsen JMA (eds) Handbook of depression and anxiety. Marcel Dekker, New York, pp 405-446
43. Zandbergen J, Pols H, Fernandez I, Griez E (1991) An analysis of panic symptoms during hypercarbia compared to hypocarbia in patients with panic attacks. J Affect Disord 23:131-136